4//SEC Filing
Carberry David 4
Accession 0000899243-22-031345
CIK 0001537917other
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 6:00 PM ET
Size
22.1 KB
Accession
0000899243-22-031345
Insider Transaction Report
Form 4
Carberry David
Director
Transactions
- Disposition to Issuer
Common Stock
2022-09-16−100,000→ 0 total - Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−25,000→ 0 totalExercise: $2.95Exp: 2027-03-28→ Common Stock (25,000 underlying) - Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−50,000→ 0 totalExercise: $2.33Exp: 2028-08-26→ Common Stock (50,000 underlying) - Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−75,000→ 0 totalExercise: $2.90Exp: 2028-05-24→ Common Stock (75,000 underlying) - Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−65,000→ 0 totalExercise: $1.22Exp: 2030-08-19→ Common Stock (65,000 underlying) - Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−50,000→ 0 totalExercise: $1.18Exp: 2029-08-22→ Common Stock (50,000 underlying) - Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−88,000→ 0 totalExercise: $1.10Exp: 2031-08-23→ Common Stock (88,000 underlying) - Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−88,000→ 0 totalExercise: $1.10Exp: 2032-08-23→ Common Stock (88,000 underlying)
Footnotes (8)
- [F1]Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 4,382 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares.
- [F2]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 1,094 shares of Syros common stock for $67.32 per share, after giving effect to the Reverse Split.
- [F3]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,286 shares of Syros common stock for $66.18 per share, after giving effect to the Reverse Split.
- [F4]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $53.17 per share, after giving effect to the Reverse Split.
- [F5]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $26.93 per share, after giving effect to the Reverse Split.
- [F6]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,848 shares of Syros common stock for $27.84 per share, after giving effect to the Reverse Split.
- [F7]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $25.10 per share, after giving effect to the Reverse Split.
- [F8]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split.
Documents
Issuer
TYME TECHNOLOGIES, INC.
CIK 0001537917
Entity typeother
Related Parties
1- filerCIK 0001435152
Filing Metadata
- Form type
- 4
- Filed
- Sep 15, 8:00 PM ET
- Accepted
- Sep 16, 6:00 PM ET
- Size
- 22.1 KB